USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 19.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 110,486 shares of the company’s stock after selling 27,260 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in USANA Health Sciences were worth $4,190,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of USNA. KBC Group NV raised its holdings in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. Centiva Capital LP acquired a new stake in USANA Health Sciences in the 3rd quarter valued at approximately $213,000. BOKF NA raised its stake in USANA Health Sciences by 99.4% during the 2nd quarter. BOKF NA now owns 5,526 shares of the company’s stock valued at $250,000 after acquiring an additional 2,755 shares in the last quarter. Quest Partners LLC acquired a new position in USANA Health Sciences during the 3rd quarter worth $250,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of USANA Health Sciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares in the last quarter. Institutional investors own 54.25% of the company’s stock.

Insider Activity at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 23rd.

USANA Health Sciences Stock Performance

USNA opened at $37.31 on Friday. The company has a market capitalization of $711.13 million, a PE ratio of 13.18, a P/E/G ratio of 1.30 and a beta of 0.89. The stock’s fifty day moving average is $37.86 and its 200-day moving average is $41.14. USANA Health Sciences, Inc. has a one year low of $34.15 and a one year high of $54.81.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. During the same period in the previous year, the business earned $0.59 earnings per share. On average, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.